Gokmen, A. Et Al. 2018. Gemcitabine, dexamethasone, and cisplatin (GDP) as an effective therapy as salvage and mobilization regimen in patients with relapsed or refractory Hodgkin lymphoma.. JOURNAL OF CLINICAL ONCOLOGY , vol.36, no.15 .

Gokmen, A., Soydan, E., Gokgoz, Z., Kurdal, M., Tek, I., Ilhan, O., ... Arslan, O.(2018). Gemcitabine, dexamethasone, and cisplatin (GDP) as an effective therapy as salvage and mobilization regimen in patients with relapsed or refractory Hodgkin lymphoma.. JOURNAL OF CLINICAL ONCOLOGY , vol.36, no.15.

Gokmen, Ayla Et Al. "Gemcitabine, dexamethasone, and cisplatin (GDP) as an effective therapy as salvage and mobilization regimen in patients with relapsed or refractory Hodgkin lymphoma.," JOURNAL OF CLINICAL ONCOLOGY , vol.36, no.15, 2018

Gokmen, Ayla Et Al. "Gemcitabine, dexamethasone, and cisplatin (GDP) as an effective therapy as salvage and mobilization regimen in patients with relapsed or refractory Hodgkin lymphoma.." JOURNAL OF CLINICAL ONCOLOGY , vol.36, no.15, 2018

Gokmen, A. Et Al. (2018) . "Gemcitabine, dexamethasone, and cisplatin (GDP) as an effective therapy as salvage and mobilization regimen in patients with relapsed or refractory Hodgkin lymphoma.." JOURNAL OF CLINICAL ONCOLOGY , vol.36, no.15.

@article{article, author={Ayla Gokmen Et Al. }, title={Gemcitabine, dexamethasone, and cisplatin (GDP) as an effective therapy as salvage and mobilization regimen in patients with relapsed or refractory Hodgkin lymphoma.}, journal={JOURNAL OF CLINICAL ONCOLOGY}, year=2018}